Skip to content
OpenCapital
Get started

OS Therapies OSTX D&A

D&A at other companies

Avalo Therapeutics logo
Avalo TherapeuticsAVTX
$17K-87.4%

Other financials

Income statement

See full
Operating income-$10.2M-103%
Net income-$10.4M-168%
EPS (diluted)-$0.27-50.0%

Balance sheet

See full
Cash & equivalents$917.6K-69.1%
Total debt$20.0M—
Total equity-$10.8M-159%
Total assets$7.3M+71.7%

Cash flow

See full
Operating cash flow-$4.6M-32.6%
CapEx$316.4K—
Free cash flow-$3.7M—

Valuation

See full
Market cap$84.62M+65.5%
Enterprise value$103.7M—

Returns & leverage

See full
Return on equity470%—
Debt / equity-1.8×—
Current ratio0.1×-1.1×

Where this comes from

Reported directly by OS Therapies in its filing.

Tagged under the XBRL concept us-gaap:DepreciationAndAmortization.

The official record: OS Therapies’s 10-Q, filed May 18, 2026, on SEC EDGAR. View the filing →

Ask your AI about OS Therapies's d&a.

Connect your AI assistant and compare it to peers, right in your chat.

Connect your AI
Harbor at dusk
Claude

Questions, answered.

What is OS Therapies's D&A?
OS Therapies (OSTX) reported D&A of $124.94K in Q1 2026.
How has OS Therapies's D&A changed year-over-year?
OS Therapies's D&A increased by 17876.7% year-over-year, from $695 to $124.94K.
What is the long-term trend for OS Therapies's D&A?
Over 2 years (2023 to 2025), OS Therapies's D&A has grown at a 827.6% compound annual growth rate (CAGR), from $4.22K to $363.09K.
What does D&A mean?
Non-cash expense representing the systematic allocation of tangible asset costs (depreciation) and intangible asset costs (amortization) over their useful lives.